BioMarin Pharmaceutical Inc. (BMRN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

BioMarin Pharmaceutical Inc. (BMRN) closed at USD 55.14 on 2026-10-14, a change of +3.1 % over the past year, with a market capitalization of USD 10.85B.

BioMarin Pharmaceutical Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

BioMarin Pharmaceutical Inc. key figures

Previous close

USD 55.14 (2026-10-14)

1-year change

+3.1 %

Market cap

USD 10.85B

Enterprise value

USD 14.18B

P/E ratio (trailing)

151.49

P/E ratio (forward)

8.45

EPS (trailing)

0.37

EPS (forward)

6.64

PEG ratio

0.32

Price to book

1.72

Revenue growth

19.9 %

Earnings growth

-81.3 %

Dividend per share (trailing)

0.00

Short ratio

5.73

Employees

3,221

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for BioMarin Pharmaceutical Inc. and compare it with other stocks.